Abstract
The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely multidisciplinary way requiring surgeons, hepatologists, interventional radiologists, and oncologists. This review describes the molecular pathogenesis of HCC, explores current and future treatments based on these pathways, and describes how these new therapies may augment existing approaches to HCC treatment.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / enzymology
-
Humans
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
-
Intracellular Signaling Peptides and Proteins / metabolism*
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / enzymology
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / metabolism*
-
Pyridines / therapeutic use*
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Receptors, Vascular Endothelial Growth Factor / metabolism*
-
Sorafenib
-
TOR Serine-Threonine Kinases
Substances
-
Angiogenesis Inhibitors
-
Benzenesulfonates
-
Intracellular Signaling Peptides and Proteins
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Niacinamide
-
Sorafenib
-
MTOR protein, human
-
Receptors, Vascular Endothelial Growth Factor
-
Protein Serine-Threonine Kinases
-
TOR Serine-Threonine Kinases